Long-term follow-up study of TPIP for PH-ILD
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial is a long-term follow-up study for people who already completed a previous study of an inhaled treprostinil medication (TPIP) for pulmonary hypertension caused by interstitial lung disease (PH-ILD). It tests whether continued treatment with TPIP is safe and effective over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the previous TPIP study (INS1009-311).
- You cannot have had serious side effects from TPIP in the earlier study that the doctor thinks would make it unsafe to continue.
- You cannot be taking other PAH medications (like prostacyclins, bosentan, ambrisentan, macitentan, or riociguat) except for sildenafil or tadalafil.
- You must have pulmonary hypertension specifically from interstitial lung disease (not from other causes like heart disease, blood clots, or COPD).
- You cannot have left-sided heart failure or heart failure with preserved ejection fraction (HFpEF).
- You must not be allergic or hypersensitive to treprostinil or any ingredient in TPIP (like mannitol or leucine).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an inhaled powder medication called TPIP (treprostinil palmitil inhalation powder) to see if it can improve symptoms and exercise ability in people who have both interstitial lung disease and pulmonary hypertension. The study will compare TPIP against a placebo (a dummy treatment without the active drug) to understand how well it works and if it is safe.
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
This trial tests an inhaled medication called treprostinil palmitil to see if it can slow the decline of lung function in people with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. It's for people whose lung disease is getting worse despite standard care, and it may help preserve their breathing ability.
This program provides access to an inhaled medication called treprostinil for people who have pulmonary hypertension (high blood pressure in the lungs) related to interstitial lung disease (a type of lung scarring). The treatment aims to improve symptoms and quality of life.
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.